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Background:  presently there are few data reporting on a direct comparison between Edwards SAPIEN valve (ESV) and Medtronic CoreValve 
(MCV) within a single center. Our aim is to describe clinical outcome after transcatheter aortic valve implantation (TAVI) performed with the two 
commercially available valves.
Methods:  One-hundred seventy consecutive patients treated via the trans-femoral approach from November 2007 to July 2010 were included in 
the analysis.
Results: Ninety-nine patients were treated with a ESV and 71 with a MCV. Between the two groups there were no difference in baseline clinical 
characteristic except for mean aortic annulus diameter which was predictably smaller in the ESV patients (23.0±1.6 vs. 24.1±1.8, p<0.001). 
Procedural success rate was 96% in the ESV group and 93% in the MCV group. MCV implantation was characterized by a significantly higher rate 
of valve embolization (four cases vs. none, p=0.017) and need for a second device, “valve after valve” procedure, (6 cases vs. none, p=0.003). 
Permanent pacemaker implantation was more frequently implanted in MCV compared to ESV patients (21% vs. 6%, p=0.003). At 30-day outcome 
no significant difference were found between ESV and MCV in terms of major vascular complication (20% vs. 19.7%), cerebrovascular events (3% vs. 
2.8%), MACCE (12% vs. 19%) and death (1% vs. 4.2%). At one year clinical follow-up, no significant difference were found in terms of death (22% vs. 
31%, ESV and MCV respectively) cardiovascular death rate (10% vs. 22%) and sudden death (4% vs. 6%).
Conclusions:  In conclusion, a direct comparison between the two commercially available TAVI valves showed that ESV and MCV are equivalent in 
terms of procedural success rates, major vascular complications and cardiovascular death. A permanent pacemaker is significantly more required in 
patients tread with MCV
